Globe on blue background as globalization concept

Ta ditt projekt utomlands

Här hittar du information och idéer om hur du kan ta ditt projekt utomlands och göra det mer internationellt.

Letar du efter seminarier och event, kan du även titta i vårt kalendarium.

Hitta snabbt:

International funding and access to resources: General

International funding and access to resources: Covid-19/SARS-COV-2


Current International opportunities relevant to Life Science


DIGI-B-CUBE är ett EU-projekt finansierat av Horisont 2020, som tillhandahåller finansiering, support och nätverksmöjligheter för små och medelstora företag inom hälsa och ICT. (DIGI-B-CUBE – Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries, Grant agreement no: 824920, INNOSUP-01-2018)

Öppna utlysningar finner ni på DIGI-B-CUBE’s hemsida: Open Calls -DIGI-B-CUBE. Ansökning sker direkt till DIGI-B-CUBE och enligt projektets regelverk.

Ansökningarna uppmuntras från SMF som arbetar inom hälso- och sjukvård, medicin, biotech, biofarma, ICT och relaterade områden (t.ex. robotik, automatisering, elektronik, nanotechnologi mm.)

Early warning for epidemics

EIC Horizon Prize for ‘Early Warning for Epidemics’ Epidemics-EICPrize-2020

Deadline 16 Feb 2021

The challenge is to develop a scalable, reliable and cost-effective early warning system prototype to forecast and monitor vector-borne diseases in order to contribute to the prevention of outbreaks mitigating their impact on local, regional and global scales and providing support to existing elimination efforts.

Expected Impact:

  • A reliable, cost-effective and scalable early warning system prototype to forecast and monitor vector-borne diseases, which should encompass innovative technological solutions integrating big data derived from different sources (e.g. space-borne, airborne, in-situ and citizen observations) in Earth observation domain, including climate data, vector-related modelling, meteorology, and geo-located information related to vector borne disease outbreaks and behaviour. These should be interoperable with public health data and other socio-economic data.
  • Demonstration of the prototype at local level, taking into account any relevant societal factors in the chosen geographical area. It should be compatible for use with data coming from existing multi-disciplinary networks comprising health, humanitarian aid and emergency management actors, in order to leverage data and information from these networks, as well as to showcase the operational potential and added value of the solution.


2021 EURIPIDES² / PENTA. PENTA targets transnational innovation supporting National priorities in micro and nanoelectronics enabled systems and applications. EURIPIDES² focuses on smart electronic systems and smart systems integration from components to systems.
One of the 10 focus areas is Health and Wellbeing, other potential areas of interest are: Digital Industry, Digital Life and Materials and Manufacturing. Deadline 26 February 2020.

Horizon Europe

Program launch är framflyttad april/maj 2021. Det blir därför en försening om cirka fyra månader, om det inte blir fler förseningar, förstås.

En sammanfattning om Horizon Europe

Uppdaterad information om Horizon Europe  


EU-kommissionen planerar ett virtuellt lanseringsevent för Horisont Europa den 2 februari 2021 (kan bli försenat).

Mer information om hur man deltar och registrerar sig till kommisionens lanseringsevent.

Vinnovas lanseringsevent den 10 februari 2021, kl. 9.30-16.30

Anmälan till Vinnovas lanseringsevent.

Mission Cancer

Conquering cancer, mission possible proposal från september 2020

Mer information on Mission Cancer

The European Commission has opened a public consultation on: “Europe´s Beating Cancer Plan”. Här kan du nå konsultationen


NextGenerationEU is a €750 billion temporary recovery instrument to help repair the immediate economic and social damage brought about by the coronavirus pandemic. Post-COVID-19 Europe will be greener, more digital, more resilient and better fit for the current and forthcoming challenges.

Programmet kommer att innehåller de hälsorelaterade programmen Preparedness, recovery and resilience, genom en “Recovery and Resilience Facility, rescEU” och ett nytt hälsoprogram, EU4Health.

– Vinnovas lanseringsevent den 10 februari 2021, kl. 9.30-16.30 Anmälan:


EU4Health informationsseminarium

22 januari kl 10.00-12.00. Information om Public Health, Medicines, Vaccines and Medical Devices samt Health Systems.

Mer information om informationsseminariet om EU4Health

More …

Svenska Paneuropaföreningen i samarbete med EU-kommissionen i Sverige kommer att sända ett seminarium ”Europa och USA med Joe Biden som president – nya möjligheter och nya krav” 18 januari kl. 14.00 – 15.00.

Seminariet livesänds via Svenska Paneuropaföreningens facebooksida.

EUs IP-kontoret erbjuder bland annat gratis IP-stöd till småbolag. Nu har de lanserad en SME FUND där de utlyses finansiell stöd av upp till 1500 EUR till SMF för IP skydd. 

Läs mer om fonden.

USA opportunity. The Swedish American Chamber of Commerce Life Science Bridge helps Life Science companies find the right contacts to enter, access and expand on the U.S. market, in three major regions: San Diego, San Francisco and Boston.

International funding and access to resources: Covid-19/SARS-COV-2

Aktuella anbudsmöjligheter för Covid-relaterade produkter och tjänster inom EU-området.

COVID International Funding Opportunities


all CovidX  – Accelerate market ready data solutions for Covid-19

  • Single Player (100K€): EU Companies with data solutions for COVID-19 and validation in COVID-X clinical sites
  • Team Player (150K€): EU Companies working with healthcare providers to validate data solutions for COVID-19
  • Deadline 27/1
  • Information and application links

H2020 EIC work programme. The European Innovation Council (EIC) pilot supports researchers and innovators developing breakthrough innovations with the potential to create new markets and boost jobs, growth and prosperity in Europe. Multiple cut off dates. Budget multiple between about 0.5-3M EURO. To prepare for applying to an EIC pilot call, please go to the ‘EIC pilot Web Page’, which will direct you to the most appropriate funding scheme for your needs. The ‘EIC pilot Web Page’ will channel you through to the Horizon 2020 Funding & Tenders Portal, which contains all the practical information you need to participate.

H2020 Technologies for first responders Call ID: H2020-SU-SEC-2018-2019-2020 Research and Innovation Action. Proposals are invited to propose novel solutions improving the protection of first responders against multiple and unexpected dangers or enhancing their capacities by addressing related research and innovation issues.

SmartEES. SmartEEs203-2020 call: SmartEEs2 project would like to directly contribute to reducing the spread of COVID19 and other viruses with flexible & wearable electronics as solutions in the field of prevention, diagnostics, therapy, etc. Therefore, SmartEEs2 will preferentially support application experiment proposals related to this thematic, particularly under the 1st cut-off date.
Multiple cut off dates
15 Jan 2021
7 May 2021
31 Aug 2021
Financial support available for an Application Experiment is up to 100 k€
– Experimenting and testing end-product ideas with FWE technologies
– Support to manufacturing of FWE based end-products including upscaling

EGI. For Scientific institutes, projects and teams addressing COVID-19 research. By applying to the call, the applicants will receive direct technical support, compute capacity and tools to speed up their research tasks.

ECH Alliance. DIGI-B-CUBE project launched an open call for funding on 22nd April 2020, to support projects focusing on integrating digital innovations and disruptive technologies across the Medical Diagnostics and related value chains.
Multiple deadlines:
3 Feb 2021
27 Oct 2021
Budget: SMEs (incl. new start-ups) in health, medicine, biotech, biopharma, IT or related sectors (robotics, automation, electronics, nanotech etc.) can apply for equity-free funding up to €60,000
A consortium consisting of minimum 2 SMEs from at least 2 different sectors (Example: An SME from healthcare/medicine/biotech/biopharma + An SME from IT and related sectors)

EOSC – Fast-track co-creation funding for COVID-19 related activities. Activities and actions that deploy open science methods and resources, and make use of the EOSC communities in order to address issues related to COVID-19. Deadline: Applications will be evaluated on a weekly basis. Budget: Secretariat will fund initiatives related to EOSC for an amount of max 45.000 EUR. A fast track procedure has been created. See full details

Scottish Government. If you have a digital product, service or innovation that may be of use in the response to COVID-19 please contact Scottish Government

UKRI. Research and Innovation ideas to address COVID-19. Deadline Proposals can be received under this call at any time and will be assessed on a rolling basis. For collaboration with UK-based businesses UKRI invites UK Principal Investigators (PIs) to include international co-investigators from anywhere in the world on proposals to the majority of our research funding schemes

Imperial College London. COVID-19 funder guidance. For collaboration with UK-based researchers and businesses


  • Bill and Melinda Gates Foundation/Wellcome/Mastercard/Chan Zuckerberg Initiative COVID 19 Therapeutics Accelerator funding will help strengthen detection, isolation and treatment efforts; protect at-risk populations; and develop vaccines, treatments and diagnostics. The R&D efforts are focused on developing new drugs, as well as exploring the possibilities to repurpose existing medicines. This work will leverage the power of partnership to develop, manufacture, and distribute effective treatments—and quickly. Total call budget $150M USD The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact
    The COVID-19 Therapeutics Accelerator will work closely with the World Health Organization, government and private sector funders, and global regulatory and policy-setting institutions. It will have an end-to-end focus – from drug pipeline development through to manufacturing and scale-up – and will provide fast and flexible funding at key stages of the process.
    Pressmeddelande 9 dec 2020


  • NIH to Launch Public-Private Partnership to Speed COVID-19 Vaccine and Treatment Options. There will be four fast-track focus areas, each of which will be led by a highly motivated working group of senior scientists representing government, industry and academia. Opportunity not yet published. Collaboration is emphasized. Many NIH programmes are open to international partners.
  • DHHS. Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional). Deadline 10 March 2023. Budget is not stated. Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement and procedures for foreign institutions described throughout the Application Guide.
  • National Science Foundation (NSF) NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
    All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to NSF encourages the research community to respond to this challenge through existing funding opportunities.
    In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to the availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events.
  • FDA. Coronavirus Treatment Acceleration Program (CTAP). FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful.
  • BARDA Broad Agency Announcement (BAA) BARDA will continuously review and expedite COVID-19 response related white papers and full proposals 31 Oct 2020 Inquiries should be sent to COVID-19 response related Areas of Interest includes:
    AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
    AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
    AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
    AOI 8.3 COVID-19 Vaccine
    AOI 9.2 COVID-19 Therapeutics
    AOI 9.3 Immunomodulators or therapeutics targeting lung repair
    AOI 9.5 Pre-exposure and post-exposure prophylaxis
    AOI 10 Respiratory protective devices
    AOI 11 Ventilators
    AOI 17 Advanced Manufacturing Technologies
  • DARPA Office-wide Broad Agency Announcements (BAA) DARPA publicizes funding opportunities primarily by posting BAAs that formally solicit proposals tied to program-specific areas of research and development.
    In addition, each DARPA technical office maintains an “office-wide” BAA that offers a mechanism for researchers to reach DARPA with an idea that may fall outside of DARPA’s current priorities, but that the proposer feels could be valuable to national security office-wide BAAs that are currently active:
    Microsystems Technology (closes 13 March 2022)
    Strategic Technology (closes 1 March 2021).
    DARPA is always interested in new ideas and emerging technologies and solutions. The DARPA technical offices that are focused on these efforts are the Defense Sciences Office (DSO) and the Biological Technology Office (BTO), both of which have Office-Wide Broad Agency Announcements (BAA) that are open for the submission of new ideas at any time
  • PA-19-056. NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) 3 cut off deadlines per year: 5 June 2020, 5 Oct 2020, 5 Feb 2021, 5 June 2021 etc Application budgets are not limited but need to reflect the actual needs of the proposed project The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators’ specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs)
  • NOT-EB-20-007. Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19). Multiple due dates. Multiple target opportunities for this Notice.
  • PA-18-418. NIBIB Research Project Grant (R01 Clinical Trial Required) Multiple cut off dates per year NIBIB will only support R01 applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development.
  • PAR-18-530. Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 – Clinical Trial Optional) Multiple cut off dates per year Stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand the disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage the disease.
  • PAR-20-155. Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional). Multiple cut off dates per year Stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other diseases
  • PAR-18-433. NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional) 3 cut off deadlines per year: 16 June 2020, 16 Oct 2020, 16 Feb 2021, 16 June 2021 etc Max $275,000 direct costs over a maximum two-year funding period. No more than $200,000 direct costs may be requested in a single year
    These studies are expected to lead to breakthroughs in the development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve a considerable risk that should be balanced by the potential high impact on human health and related research.
  • PA-19-052. NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) Deadline 16 June 2020, 16 Oct 2020, 16 Feb 2021, 16 June 2021 etc Until the end of 2021. Max $50,000 in direct costs per year
    Supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology
  • NIDCD, HHS. Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) Notices of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to multiple areas.
  • PA-18-591. Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) Deadline Jan 26 2021 Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
    Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
    Other: A mechanism that is not a grant or cooperative agreement. Examples include access to research resources or pre-applications
  • PA-18-935. Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional Deadline Jan 25, 2022. Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
    Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities.
  • NOT-AI-20-034. Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Deadline 25 March 2021 Application budgets are not limited but need to reflect the actual needs of the proposed project.
    NIAID is issuing this Notice of Special Interest to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19

International information and access to resources

  • European Area Coronavirus Platform. Collected information regarding related European research and innovation. Continuously updated.
  • EU Coronavirus research and innovation. Information site about EU supported research and innovation projects and initiatives to tackle the spread of coronavirus and preparedness for other outbreaks. This includes
    – Advice for sponsors of clinical trials for COVID-19 treatments and vaccines
    – Advice for sponsors of clinical trials affected by the pandemic
    – Guidance on regulatory expectations and flexibility (human medicines)
    – Guidance on regulatory expectations and flexibility (veterinary medicines)
  • EMA. Guidance for medicine developers and companies on COVID-19
  • EGI Foundation. Guidelines for open access to publications, data and other research outputs. Guidelines for Horizon 2020 projects working on the 2019 coronavirus disease (COVID-19), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related topics
  • The COVID-19 Data Portal. The aim of the COVID-19 Data Portal is to facilitate data sharing and analysis and to accelerate coronavirus research. The COVID-19 Data Portal will enable researchers to upload, access and analyse COVID-19 related reference data and specialist datasets. The COVID-19 Data Portal will be the primary entry point into the functions of a wider project, the European COVID-19 Data Platform
  • BBMRI, ECRIN och EATRIS. COVID-19 Fast Response Service. The COVID-19 Fast Response Service is a coordinated and accelerated procedure for researchers to access the academic facilities, services and resources of the three collaborating medical research infrastructures
  • BBMRI-ERIC. Resources from biobanks across Europe available for research on COVID-19. Contains continuously updated document on the list of available resources that researchers working against COVID-19 can access via the BBMRI-ERIC network
  • Computational Structural Biology group @Utrecht University. HADDOCK, a biomolecular simulations platform. HADDOCK (High Ambiguity Driven protein-protein DOCKing) is an integrative platform developed at Utrecht University for the modelling of biomolecular complexes and is one of the WeNMR thematic services. HADDOCK can support complex simulation projects, and benefits from the distributed computing infrastructure of EGI. In the context of COVID-19 related research it can, for example, model interaction between virus proteins and human one, or support the docking of small molecules to targets such as the COVID-19 protease. The tool is offered by the Bijvoet Center of the Utrecht University, Netherlands, is supported by the EOSC-hub H2020 project and is also accessible through the European Open Science Cloud Portal.
  • ELIXIR resources for COVID-19 research. ELIXIR, the ESFRI Research Infrastructure for life science data, provides a range of services and resources, that can be used by researchers and consortia working on SARS-CoV-2 research via ELIXIR Nodes. ELIXIR provides a range of services that you can use for studying the SARS-CoV-2 coronavirus and the COVID-19 disease.
  • EMBL-EBI COVID-19 pathogen portal Biomedical data resources. (Länken kan verka bruten men det är den inte.) EMBL-EBI is gathering and sharing data resources as they become available. This includes sequences of outbreak isolates and records relating to coronavirus biology. Researchers can also find instructions for submitting data to the European Nucleotide Archive (ENA). The COVID-19 Data Portal enables researchers to upload, access and analyse COVID-19 related reference data and specialist datasets
    Covid-19 Data portal
  • ERINHA: High containment facilities for pre-clinical research. ERINHA offers access to a large range of high containment (BSL3 & BSL4) in-vitro and in-vivo capacities to facilitate a wide variety of studies on SARS-CoV-2/COVID-19. These capacities include: In vitro research capacity In vivo research capacity: Support for the coordination of pre-clinical research activities, project management, advice on protocols
  • The European Synchrotron Radiation Facility Extremely Brilliant Source (ESRF-EBS). Access to a unique combination of state-of-the-art facilities and common platforms for structural biology and bio-imaging for COVID-19 related research projects. Access will be granted with the aim to contribute to the international scientific effort to overcome the COVID-19 pandemic, and the available facilities include its cryo-electron microscope and its structural biology beamlines. For any urgent project on Covid-19 that may need the support of the ESRF expertise and the exceptional use of ESRF facilities, please contact Jean Susini ( or Harald Reichert (, Directors of Research, or Gordon Leonard (, Head of the Structural Biology Group. All proposals will be considered on a case-by-case basis and followed up rapidly.
  • EU-OPENSCREEN. Access to pilot compound library. EU-OPENSCREEN and its partner sites are actively involved in the study of SARS-CoV-2, aiming to identify therapeutics and search for diagnostics. EU-OPENSCREEN provides a fast access track for scientist wishing to use their pilot compound library for their COVID-19 related research activities. Contact EU-OPENSCREEN directly for access.
  • COST. COST Actions unite efforts in the fight against COVID-19. STRATAGEM COST Action (New diagnostic and therapeutic tools against multidrug-resistant tumours) has created a “Task Force” of researchers contributing to Covid-19 research. The main objective of this task force is to synthesize new drugs or identify FDA approved drugs which could be repurposed as antiviral agents against SARS-CoV-2 and contribute to diagnosis or prognosis of Covid-19. Actions:
    – New diagnostic and therapeutic tools against multidrug-resistant tumours (Stratagem)
    – Catalysing transcriptomics research in cardiovascular disease (CardioRNA)
    – A multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)
    – Open Multiscale Systems Medicine (OpenMultiMed)
    – European Network on Myalgic
    – Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE)
    – Anti-Microbial Coating Innovations to prevent infectious diseases (AMICI)
  • The Institut Laue-Langevin (ILL): Rapid access to beam time. ILL plans to run 2 more cycles in 2020 which will constitute a significant opportunity to perform early research related to Covid-19 on many of their neutron scattering instruments. In addition to the instruments, there is access to deuteration facilities and shared biology and soft matter facilities with partner institutes on the EPN campus – the ESRF, EMBL and IBS. Apply for beam time.
  • INFRAFRONTIER Model mammalian genome resources. INFRAFRONTIER has created a dedicated webpage listing all its specific resources and services for COVID-19 research. This site also lists the INFRAFRONTIER nodes that offer emergency archiving of mouse lines for laboratories that cannot maintain their colonies due to the coronavirus crisis. For information go to INTRAFRONTIER COVID-19 RESOURCES
  • WHO. Coronavirus Disease (COVID-19) Pandemic information site.


BIA, UK Bioindustry Association, har tagit fram en webbplats för hur life science-företag kan förhålla sig till Brexit och de nya spelreglerna.
The BIA Brexit Portal

EU-kommissionen: Avtalet om Storbritanniens utträde ur EU – vad innebär det för Sverige? Film (otextad).